Ventana Medical Systems, Inc.

Cell Signaling Technology, Inc.

Becton Dickinson and Company Limited

Quintiles Transnational Corporation

Amgen Inc.

Cell Analysis Systems, Inc.

American Molecular Laboratories Inc.

Biocosmeceuticals, LLC

Targeted Molecular Diagnostics

Sarah S. Bacus

Sarah S Bacus

Bradley L Smith

James W Bacus

Xiao-Dong Yang

David Haskett Lynch

Gisela Schwab

Jason Hill

Christopher A Hamm

Pamela Lockbaum

The present disclosure provides method for determining an immune response score (irScore), the method comprising: determining a number of differentially expressed genes that have are implicated in anti-tumor immune cell signaling/activation; determining a number of differentially expressed genes that are implicated in immunosuppression, wherein the irScore=X, wherein X is the number of differentially expressed genes that are implicated in anti-tumor immune cell signaling/activation, and wherein low refers to 1-4 differentially expressed genes that are implicated in immunosuppression, medium refers to 5-9 differentially expressed genes that are implicated in immunosuppression, and high refers to 10 or more differentially expressed genes that are implicated in immunosuppression.

Methods of determining an immune response score

This invention provides methods for determining or predicting response to cancer therapy in an individual using differential image analysis of immunohistochemically stained tumor samples.

Method and quantification assay for determining c-kit/SCF/pAKT status

This invention provides methods for determining or predicting response to HER2-directed therapy in an individual.

Method for predicting the response to HER2-directed therapy

Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.

Compositions and methods for treatment of vitiligo

Methods are disclosed for determining whether organ toxicity, particularly cardiotoxicity, will occur in a patient selected for treatment with various kinase inhibitors, such as tyrosine kinase inhibitors, more particularly erbB inhibitors such as Herceptin. In addition, methods are disclosed for determining whether a potential drug is likely to produce a cardiotoxic effect. The methods involve analyzing lipid levels or the expression fatty acid oxidation enzymes, pAMP activated protein kinase, glucose uptake, to determine whether a fatty acid oxidation disorder is present. The identification of a fatty acid oxidation disorder can be used as a predictor of toxicity, especially cardiac toxicity, and as an indication that organ function should be carefully monitored if a drug such as a tyrosine kinase inhibitor is administered. Methods are also disclosed for protecting organs from metabolic stress and for the treatment of cells, such as adipocytes, to reduce their lipid content.

Methods for predicting cardiac toxicity

The present disclosure relates generally to methods and materials for determining the responsiveness of a subject with a disease or disorder to an inhibitor of a receptor tyrosine kinase including, for example, IGF1R. Such methods may comprise obtaining a biological sample from the subject, assaying the biological sample for one or more PIK3CA mutations, determining if one or more PIK3CA mutations are present in the biological sample, and employing the determination of one or more PIK3CA mutations in the biological sample to predict responsiveness of the subject to the receptor tyrosine kinase inhibitor.

Methods for predicting responsiveness of a cancer cell to an anti-IGFR1 antibody by analysis of mutations in PIK3CA

The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject's sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinically positive outcome. Cellular receptors, ligands to those receptors and molecules involved in the programmed cell death pathway are examples of targeted therapy markers that might be used in the present invention.

Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor

The invention relates to a method for determining the response to cancer therapy in an individual using image analysis.

Method for determining the response to cancer therapy

This invention provides methods for determining or predicting response to cancer therapy in an individual.

Method for predicting response to epidermal growth factor receptor-directed therapy

The present invention provides a method for determining expression levels of one or a multiplicity of target proteins in a tissue or cell sample.

Method for quantitating a protein by image analysis

Methods and compositions for cancer therapy and for prognosticating

A method for prognosticating the effectiveness of a chemotherapy using monoclonal antibodies and ligand molecules. The putative anti-cancer agent has binding specificity for a oncogenic receptor molecule on the membrane of a cancer cell, such as HER-2/neu. When the putative agent binds to the oncogenic receptor, the receptor translocates from the membrane to the cytoplasm or perinucleus of the cancer cell, accompanied by a transient increase in the total cellular content of the receptor, and results in terminal cell differentiation. The efficacy of the agent in vivo can be determined in vitro by treatment of biopsied cancer cells with the agent and subsequent examination of the cells for evidence of terminal cell differentiation. Such evidence includes morphological change, reduction in cell growth, or production of chemicals associated with the mature phenotype. Additionally, treated cells may be examined with immunohistochemicals specific for the oncogenic receptor, to determine translocation of the receptor from the membrane to the cytoplasm or perinucleus. Quantification of receptor levels in treated cells by measuring optical densities after staining can be used to determine translocation, as well as a transient increase in total cellular content of the receptor.

Growing community of inventors

Hinsdale, IL, United States of America

Sarah S Bacus